Q-omics provides the consensus-scored SOCS2 profile across patient tissues and cancer cell-line models. SOCS2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SOCS2 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, SOCS2 RNA expression shows 18,299 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, KIRP, and CCRCC as cancer lineages where SOCS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOCS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOCS2 survival associations across molecular data types. SOCS2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOCS2 RNA expression–survival associations across cancer types. High SOCS2 expression shows unfavorable associations in UVM, LGG and BLCA, but favorable associations in KIRC, LIHC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SOCS2 RNA expression.
This table summarizes SOCS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SOCS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOCS2 shows lower tumor expression in KIRP, KICH, KIRC, THCA, LUAD and LIHC. The KIRP box plot shows higher SOCS2 RNA expression in normal versus tumor tissue (log2 FC = −2.329, t-test p < 0.001).
This table shows molecular features associated with SOCS2 in patient tissues and cancer cell lines. In patient samples, SOCS2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SOCS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
